Portal de Periódicos da CAPES

Tropifexor, a highly potent FXR agonist, produces robust and dose-dependent reductions in hepatic fat and serum alanine aminotransferase in patients with fibrotic NASH after 12 weeks of therapy: FLIGHT-FXR Part C interim results

2020; Elsevier BV; Volume: 52; Linguagem: Inglês

10.1016/j.dld.2019.12.129

1878-3562

Kathryn Jean Lucas, Patricia López, Eric Lawitz, Aasim Sheikh, Dov Aizenberg, Stanley H. Hsia, George Goh Bee, John M. Vierling, José Aristeu Fachini Frias, J. White, Yuichiro Eguchi, Donald J. Lazas, Guy Neff, Masato Yoneda, Salvador Augustín, Won Kim, Y. Loeffler, F Schaefer, S. Lamle, Miljen Martić, Clifford A. Brass, Arun J. Sanyal,

Endoplasmic Reticulum Stress and Disease

Introduction: FLIGHT-FXR (NCT02855164) is a phase 2 randomized, double blind, placebo-controlled, 3-part, adaptive-design study to assess the safety, tolerability, and efficacy of several doses of tropifexor (LJN452, TXR) in patients with non-alcoholic steatohepatitis (NASH). AIM: here, we present Part C prespecified interim results at W12.